[ad_1]
Researchers Danuta Skoronsky and Gaston de Serce said they came to this conclusion based on documents provided by Pfizer to the United States Food and Drug Administration.
And they mentioned in a letter published in the New England Journal of Medicine that these results are similar to those related to the vaccine, which is produced by Moderna, and that its effectiveness rate after the first dose was 92.1%.
And he warned that there could be uncertainty about the duration of protection, which is guaranteed by one dose, but vaccination with the second dose a month after the first “brings no short-term benefit.”
They said: “Given the current vaccine shortage, postponing the second dose is a matter of national security, if ignored it will certainly lead to thousands of hospitalizations and deaths from Covid-19 this winter in the United States.”
In response, Pfizer said a change in the vaccination regimen with two doses of the vaccine has not yet been evaluated, adding that this decision is left to health authorities.
It should be noted that this request may cause more controversy in the medical community, especially with the widespread vaccination operations carried out in various regions of the world.
[ad_2]
Source link
